Join
Live feed
·
PRReleasevia Quantisnow
Aravive Inc. logo

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ARAV· Aravive Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARAV (Aravive Inc.) and more on Quantisnow.